Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]

  • Awaiting development
  • GID-TA11744
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Ritlecitinib within its marketing authorisation for treating vitiligo ID6584